The Experts below are selected from a list of 7491 Experts worldwide ranked by ideXlab platform

Austin Nuschke - One of the best experts on this subject based on the ideXlab platform.

  • activity of mesenchymal stem cells in therapies for Chronic Skin Wound healing
    Organogenesis, 2014
    Co-Authors: Austin Nuschke
    Abstract:

    Chronic or non-healing Skin Wounds present an ongoing challenge in advanced Wound care, particularly as the number of patients increases while technology aimed at stimulating Wound healing in these cases remains inefficient. Mesenchymal stem cells (MSCs) have proved to be an attractive cell type for various cell therapies due to their ability to differentiate into various cell lineages, multiple donor tissue types, and relative resilience in ex-vivo expansion, as well as immunomodulatory effects during transplants. More recently, these cells have been targeted for use in strategies to improve Chronic Wound healing in patients with diabetic ulcers or other stasis Wounds. Here, we outline several mechanisms by which MSCs can improve healing outcomes in these cases, including reducing tissue inflammation, inducing angiogenesis in the Wound bed, and reducing scarring following the repair process. Approaches to extend MSC life span in implant sites are also examined.

Eleonora Iacono - One of the best experts on this subject based on the ideXlab platform.

  • Heterologous Wharton's Jelly Derived Mesenchymal Stem Cells Application on a Large Chronic Skin Wound in a 6-Month-Old Filly
    Frontiers Media S.A., 2019
    Co-Authors: Aliai Lanci, Barbara Merlo, Jole Mariella, Carolina Castagnetti, Eleonora Iacono
    Abstract:

    A complex feedback of growth factors, secreted by a variety of cell types, is responsible for the mediation of Skin healing. Despite the recent advances in Wound healing management, this fails up to 50% and Skin Wounds can still be considered one of the main causes of morbidity, both in human and veterinary medicine. Regenerative medicine, involving mesenchymal stromal cells (MSCs), is nowadays a promising solution for Skin Wound healing. Indeed, MSCs are involved in the modulation of the inflammatory local response and cell replacing, by a paracrine mode of action. Local application of equine umbilical cord Wharton's jelly MSCs (WJMSCS) was carried out in a 6-months-old filly with a non-healing Skin Wound. Heterologous WJMSCs were applied four times using a carboxymethylcellulose (CMC) gel, produced dissolving CMC in autologous plasma. At first application the mean Wound area was 7.28 ± 0.2 cm2. Four days after the last application of WJMSCs, the mean Wound area was 1.90 ± 0.03 cm2, and the Wound regression rate was +74%. No local or systemic side effects were registered after WJMSCs application and no evident exuberant scar was observed after Wound healing. At discharge, the mean Wound area was 0.38 ± 0.01 cm2 and the total regression rate was +80%. Five days later, the Wound was completely healed. In the present clinical case report, the use of WJMSCs led to promising clinical results, paving the way for possible future applications in the treatment of Chronic Wounds in horses

  • Image_1_Heterologous Wharton's Jelly Derived Mesenchymal Stem Cells Application on a Large Chronic Skin Wound in a 6-Month-Old Filly.TIFF
    2019
    Co-Authors: Aliai Lanci, Barbara Merlo, Jole Mariella, Carolina Castagnetti, Eleonora Iacono
    Abstract:

    A complex feedback of growth factors, secreted by a variety of cell types, is responsible for the mediation of Skin healing. Despite the recent advances in Wound healing management, this fails up to 50% and Skin Wounds can still be considered one of the main causes of morbidity, both in human and veterinary medicine. Regenerative medicine, involving mesenchymal stromal cells (MSCs), is nowadays a promising solution for Skin Wound healing. Indeed, MSCs are involved in the modulation of the inflammatory local response and cell replacing, by a paracrine mode of action. Local application of equine umbilical cord Wharton's jelly MSCs (WJMSCS) was carried out in a 6-months-old filly with a non-healing Skin Wound. Heterologous WJMSCs were applied four times using a carboxymethylcellulose (CMC) gel, produced dissolving CMC in autologous plasma. At first application the mean Wound area was 7.28 ± 0.2 cm2. Four days after the last application of WJMSCs, the mean Wound area was 1.90 ± 0.03 cm2, and the Wound regression rate was +74%. No local or systemic side effects were registered after WJMSCs application and no evident exuberant scar was observed after Wound healing. At discharge, the mean Wound area was 0.38 ± 0.01 cm2 and the total regression rate was +80%. Five days later, the Wound was completely healed. In the present clinical case report, the use of WJMSCs led to promising clinical results, paving the way for possible future applications in the treatment of Chronic Wounds in horses.

  • HETEROLOGOUS WHARTON’S JELLY DERIVED MESENCHYMAL STEM CELLS APPLICATION ON A LARGE Chronic Skin Wound IN A SIX-MONTH-OLD FILLY
    2019
    Co-Authors: Aliai Lanci, Barbara Merlo, Jole Mariella, Carolina Castagnetti, Eleonora Iacono
    Abstract:

    A complex feedback of growth factors, secreted by a variety of cell types, is responsible for the mediation of Skin healing. Despite the recent advances in Wound healing management, this fails up to 50% and Skin Wounds can still be considered one of the main causes of morbidity, both in human and veterinary medicine. Regenerative medicine, involving mesenchymal stromal cells (MSCs), is nowadays a promising solution for Skin Wound healing. Indeed, MSCs are involved in the modulation of the inflammatory local response and cell replacing, by a paracrine mode of action. Local application of equine umbilical cord Wharton's jelly MSCs (WJMSCS) was carried out in a 6-months-old filly with a non-healing Skin Wound. Heterologous WJMSCs were applied four times using a carboxymethylcellulose (CMC) gel, produced dissolving CMC in autologous plasma. At first application the mean Wound area was 7.28 ± 0.2 cm2. Four days after the last application of WJMSCs, the mean Wound area was 1.90 ± 0.03 cm2, and the Wound regression rate was +74%. No local or systemic side effects were registered after WJMSCs application and no evident exuberant scar was observed after Wound healing. At discharge, the mean Wound area was 0.38 ± 0.01 cm2 and the total regression rate was +80%. Five days later, the Wound was completely healed. In the present clinical case report, the use of WJMSCs led to promising clinical results, paving the way for possible future applications in the treatment of Chronic Wounds in horses

Phil Stephens - One of the best experts on this subject based on the ideXlab platform.

  • development and characterisation of a human Chronic Skin Wound cell line towards an alternative for animal experimentation
    International Journal of Molecular Sciences, 2018
    Co-Authors: M Caley, Ivan Wall, Matthew Arnold Peake, David Glyn Kipling, Peter Giles, D W P Thomas, Phil Stephens
    Abstract:

    Background: Chronic Skin Wounds are a growing financial burden for healthcare providers, causing discomfort/immobility to patients. Whilst animal Chronic Wound models have been developed to allow for mechanistic studies and to develop/test potential therapies, such systems are not good representations of the human Chronic Wound state. As an alternative, human Chronic Wound fibroblasts (CWFs) have permitted an insight into the dysfunctional cellular mechanisms that are associated with these Wounds. However, such cells strains have a limited replicative lifespan and therefore a limited reproducibility/usefulness. Objectives: To develop/characterise immortalised cell lines of CWF and patient-matched normal fibroblasts (NFs). Methods and Results: Immortalisation with human telomerase resulted in both CWF and NF proliferating well beyond their replicative senescence end-point (respective cell strains senesced as normal). Gene expression analysis demonstrated that, whilst proliferation-associated genes were up-regulated in the cell lines (as would be expected), the immortalisation process did not significantly affect the disease-specific genotype. Immortalised CWF (as compared to NF) also retained a distinct impairment in their Wound repopulation potential (in line with CWF cell strains). Conclusions: These novel CWF cell lines are a credible animal alternative and could be a valuable research tool for understanding both the aetiology of Chronic Skin Wounds and for therapeutic pre-screening.

Aliai Lanci - One of the best experts on this subject based on the ideXlab platform.

  • Heterologous Wharton's Jelly Derived Mesenchymal Stem Cells Application on a Large Chronic Skin Wound in a 6-Month-Old Filly
    Frontiers Media S.A., 2019
    Co-Authors: Aliai Lanci, Barbara Merlo, Jole Mariella, Carolina Castagnetti, Eleonora Iacono
    Abstract:

    A complex feedback of growth factors, secreted by a variety of cell types, is responsible for the mediation of Skin healing. Despite the recent advances in Wound healing management, this fails up to 50% and Skin Wounds can still be considered one of the main causes of morbidity, both in human and veterinary medicine. Regenerative medicine, involving mesenchymal stromal cells (MSCs), is nowadays a promising solution for Skin Wound healing. Indeed, MSCs are involved in the modulation of the inflammatory local response and cell replacing, by a paracrine mode of action. Local application of equine umbilical cord Wharton's jelly MSCs (WJMSCS) was carried out in a 6-months-old filly with a non-healing Skin Wound. Heterologous WJMSCs were applied four times using a carboxymethylcellulose (CMC) gel, produced dissolving CMC in autologous plasma. At first application the mean Wound area was 7.28 ± 0.2 cm2. Four days after the last application of WJMSCs, the mean Wound area was 1.90 ± 0.03 cm2, and the Wound regression rate was +74%. No local or systemic side effects were registered after WJMSCs application and no evident exuberant scar was observed after Wound healing. At discharge, the mean Wound area was 0.38 ± 0.01 cm2 and the total regression rate was +80%. Five days later, the Wound was completely healed. In the present clinical case report, the use of WJMSCs led to promising clinical results, paving the way for possible future applications in the treatment of Chronic Wounds in horses

  • Image_1_Heterologous Wharton's Jelly Derived Mesenchymal Stem Cells Application on a Large Chronic Skin Wound in a 6-Month-Old Filly.TIFF
    2019
    Co-Authors: Aliai Lanci, Barbara Merlo, Jole Mariella, Carolina Castagnetti, Eleonora Iacono
    Abstract:

    A complex feedback of growth factors, secreted by a variety of cell types, is responsible for the mediation of Skin healing. Despite the recent advances in Wound healing management, this fails up to 50% and Skin Wounds can still be considered one of the main causes of morbidity, both in human and veterinary medicine. Regenerative medicine, involving mesenchymal stromal cells (MSCs), is nowadays a promising solution for Skin Wound healing. Indeed, MSCs are involved in the modulation of the inflammatory local response and cell replacing, by a paracrine mode of action. Local application of equine umbilical cord Wharton's jelly MSCs (WJMSCS) was carried out in a 6-months-old filly with a non-healing Skin Wound. Heterologous WJMSCs were applied four times using a carboxymethylcellulose (CMC) gel, produced dissolving CMC in autologous plasma. At first application the mean Wound area was 7.28 ± 0.2 cm2. Four days after the last application of WJMSCs, the mean Wound area was 1.90 ± 0.03 cm2, and the Wound regression rate was +74%. No local or systemic side effects were registered after WJMSCs application and no evident exuberant scar was observed after Wound healing. At discharge, the mean Wound area was 0.38 ± 0.01 cm2 and the total regression rate was +80%. Five days later, the Wound was completely healed. In the present clinical case report, the use of WJMSCs led to promising clinical results, paving the way for possible future applications in the treatment of Chronic Wounds in horses.

  • HETEROLOGOUS WHARTON’S JELLY DERIVED MESENCHYMAL STEM CELLS APPLICATION ON A LARGE Chronic Skin Wound IN A SIX-MONTH-OLD FILLY
    2019
    Co-Authors: Aliai Lanci, Barbara Merlo, Jole Mariella, Carolina Castagnetti, Eleonora Iacono
    Abstract:

    A complex feedback of growth factors, secreted by a variety of cell types, is responsible for the mediation of Skin healing. Despite the recent advances in Wound healing management, this fails up to 50% and Skin Wounds can still be considered one of the main causes of morbidity, both in human and veterinary medicine. Regenerative medicine, involving mesenchymal stromal cells (MSCs), is nowadays a promising solution for Skin Wound healing. Indeed, MSCs are involved in the modulation of the inflammatory local response and cell replacing, by a paracrine mode of action. Local application of equine umbilical cord Wharton's jelly MSCs (WJMSCS) was carried out in a 6-months-old filly with a non-healing Skin Wound. Heterologous WJMSCs were applied four times using a carboxymethylcellulose (CMC) gel, produced dissolving CMC in autologous plasma. At first application the mean Wound area was 7.28 ± 0.2 cm2. Four days after the last application of WJMSCs, the mean Wound area was 1.90 ± 0.03 cm2, and the Wound regression rate was +74%. No local or systemic side effects were registered after WJMSCs application and no evident exuberant scar was observed after Wound healing. At discharge, the mean Wound area was 0.38 ± 0.01 cm2 and the total regression rate was +80%. Five days later, the Wound was completely healed. In the present clinical case report, the use of WJMSCs led to promising clinical results, paving the way for possible future applications in the treatment of Chronic Wounds in horses

M Caley - One of the best experts on this subject based on the ideXlab platform.

  • development and characterisation of a human Chronic Skin Wound cell line towards an alternative for animal experimentation
    International Journal of Molecular Sciences, 2018
    Co-Authors: M Caley, Ivan Wall, Matthew Arnold Peake, David Glyn Kipling, Peter Giles, D W P Thomas, Phil Stephens
    Abstract:

    Background: Chronic Skin Wounds are a growing financial burden for healthcare providers, causing discomfort/immobility to patients. Whilst animal Chronic Wound models have been developed to allow for mechanistic studies and to develop/test potential therapies, such systems are not good representations of the human Chronic Wound state. As an alternative, human Chronic Wound fibroblasts (CWFs) have permitted an insight into the dysfunctional cellular mechanisms that are associated with these Wounds. However, such cells strains have a limited replicative lifespan and therefore a limited reproducibility/usefulness. Objectives: To develop/characterise immortalised cell lines of CWF and patient-matched normal fibroblasts (NFs). Methods and Results: Immortalisation with human telomerase resulted in both CWF and NF proliferating well beyond their replicative senescence end-point (respective cell strains senesced as normal). Gene expression analysis demonstrated that, whilst proliferation-associated genes were up-regulated in the cell lines (as would be expected), the immortalisation process did not significantly affect the disease-specific genotype. Immortalised CWF (as compared to NF) also retained a distinct impairment in their Wound repopulation potential (in line with CWF cell strains). Conclusions: These novel CWF cell lines are a credible animal alternative and could be a valuable research tool for understanding both the aetiology of Chronic Skin Wounds and for therapeutic pre-screening.